Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice.

Khandanpour C, Krongold J, Schütte J, Bouwman F, Vassen L, Gaudreau MC, Chen R, Calero-Nieto FJ, Diamanti E, Hannah R, Meyer SE, Grimes HL, van der Reijden BA, Jansen JH, Patel CV, Peeters JK, Löwenberg B, Dührsen U, Göttgens B, Möröy T.

Blood. 2012 Nov 8;120(19):4006-17. doi: 10.1182/blood-2011-02-334722. Epub 2012 Aug 28.

2.

Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.

Botezatu L, Michel LC, Helness A, Vadnais C, Makishima H, Hönes JM, Robert F, Vassen L, Thivakaran A, Al-Matary Y, Lams RF, Schütte J, Giebel B, Görgens A, Heuser M, Medyouf H, Maciejewski J, Dührsen U, Möröy T, Khandanpour C.

Exp Hematol. 2016 Aug;44(8):713-726.e14. doi: 10.1016/j.exphem.2016.05.004. Epub 2016 May 20.

3.

Growth factor independence 1 protects hematopoietic stem cells against apoptosis but also prevents the development of a myeloproliferative-like disease.

Khandanpour C, Kosan C, Gaudreau MC, Dührsen U, Hébert J, Zeng H, Möröy T.

Stem Cells. 2011 Feb;29(2):376-85. doi: 10.1002/stem.575.

4.

NUP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis.

Forrester AM, Grabher C, McBride ER, Boyd ER, Vigerstad MH, Edgar A, Kai FB, Da'as SI, Payne E, Look AT, Berman JN.

Br J Haematol. 2011 Oct;155(2):167-81. doi: 10.1111/j.1365-2141.2011.08810.x. Epub 2011 Aug 2.

PMID:
21810091
5.

NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.

Burillo-Sanz S, Morales-Camacho RM, Caballero-Velázquez T, Vargas MT, García-Lozano JR, Falantes JF, Prats-Martín C, Bernal R, Pérez-Simón JA.

Int J Lab Hematol. 2016 Feb;38(1):64-71. doi: 10.1111/ijlh.12435. Epub 2015 Sep 29.

PMID:
26418229
6.

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.

Khandanpour C, Thiede C, Valk PJ, Sharif-Askari E, Nückel H, Lohmann D, Horsthemke B, Siffert W, Neubauer A, Grzeschik KH, Bloomfield CD, Marcucci G, Maharry K, Slovak ML, van der Reijden BA, Jansen JH, Schackert HK, Afshar K, Schnittger S, Peeters JK, Kroschinsky F, Ehninger G, Lowenberg B, Dührsen U, Möröy T.

Blood. 2010 Mar 25;115(12):2462-72. doi: 10.1182/blood-2009-08-239822. Epub 2010 Jan 14.

7.

Gfi1 integrates progenitor versus granulocytic transcriptional programming.

Horman SR, Velu CS, Chaubey A, Bourdeau T, Zhu J, Paul WE, Gebelein B, Grimes HL.

Blood. 2009 May 28;113(22):5466-75. doi: 10.1182/blood-2008-09-179747. Epub 2009 Apr 3.

8.

A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis.

Li A, Yang Y, Gao C, Lu J, Jeong HW, Liu BH, Tang P, Yao X, Neuberg D, Huang G, Tenen DG, Chai L.

J Clin Invest. 2013 Oct;123(10):4195-207. doi: 10.1172/JCI62891. Epub 2013 Sep 24.

9.
10.

Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion.

Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries K, Sauvageau G.

Blood. 2002 Jan 1;99(1):121-9.

11.

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG.

J Clin Invest. 2004 Feb;113(4):528-38.

12.

Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98-HOXA9-induced myeloid disease.

Deveau AP, Forrester AM, Coombs AJ, Wagner GS, Grabher C, Chute IC, Léger D, Mingay M, Alexe G, Rajan V, Liwski R, Hirst M, Steigmaier K, Lewis SM, Look AT, Berman JN.

Leukemia. 2015 Oct;29(10):2086-97. doi: 10.1038/leu.2015.126. Epub 2015 May 28.

PMID:
26017032
14.

STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation.

Gough DJ, Marié IJ, Lobry C, Aifantis I, Levy DE.

Blood. 2014 Oct 2;124(14):2252-61. doi: 10.1182/blood-2013-02-484196. Epub 2014 Aug 22.

16.

PBX3 is an important cofactor of HOXA9 in leukemogenesis.

Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong GM, Kunjamma RB, Ren H, He C, Wang CZ, Elkahloun AG, Valk PJ, Döhner K, Neilly MB, Bullinger L, Delwel R, Löwenberg B, Liu PP, Morgan R, Rowley JD, Yuan CS, Chen J.

Blood. 2013 Feb 21;121(8):1422-31. doi: 10.1182/blood-2012-07-442004. Epub 2012 Dec 20.

17.

HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.

Brumatti G, Salmanidis M, Kok CH, Bilardi RA, Sandow JJ, Silke N, Mason K, Visser J, Jabbour AM, Glaser SP, Okamoto T, Bouillet P, D'Andrea RJ, Ekert PG.

Oncotarget. 2013 Nov;4(11):1933-47.

18.

Cdx4 and menin co-regulate Hoxa9 expression in hematopoietic cells.

Yan J, Chen YX, Desmond A, Silva A, Yang Y, Wang H, Hua X.

PLoS One. 2006 Dec 20;1:e47.

19.

HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo.

Fischbach NA, Rozenfeld S, Shen W, Fong S, Chrobak D, Ginzinger D, Kogan SC, Radhakrishnan A, Le Beau MM, Largman C, Lawrence HJ.

Blood. 2005 Feb 15;105(4):1456-66. Epub 2004 Nov 2.

20.

The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression.

Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A, Brown EJ, Hess JL, Pear WS, Hua X.

Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1018-23. Epub 2006 Jan 13.

Supplemental Content

Support Center